UAS LABS COMPLETES SUCCESSFUL CLINICAL TRIAL
The team at UAS Laboratories LLC (Wausau, WI, USA), has historically completed clinical research on both single probiotic strains as well as blends. This commitment to research has allowed them to scientifically back their probiotic solutions for over 40 years.
Most recently, Dr. Gregory Leyer, Chief Scientific Officer, and Dr. Christopher Martoni, Principal Scientist, designed the sixth largest probiotic-digestive health clinical trial including over 300 adults. In unique fashion, they devised a 3-arm trial which analyzed the impact of two UAS exclusive strains: L. acidophilus DDS®-1 and B. lactis UABla-12™ against placebo.
When asked about the strategy Dr. Leyer stated, “While the research supporting our DDS-1 strain of L. acidophilus is copious, this clinical trial provided the opportunity to continue growing its portfolio. We have promised our partners that our foundation is built on science, and this study upholds our commitment”. He continued, “Adding B. lactis as a separate arm allowed us to evaluate two different probiotic genera for optimal performance. We are beyond thrilled with the impact both have shown on digestive health”.
To achieve the desired number of subjects, in the shortest amount of time, this study was conducted at 12 sites throughout India. The Clinical Research Organization (CRO) partner is GCP and ISO compliant with over 400 clinical and preclinical studies to their name.
Dr. Martoni, who was intimately involved in the protocol design, stated, “All 330 adult subjects met Rome IV diagnostic criteria for IBS. After a two-week run in period they were evaluated at day 0, 21 and 42 for abdominal pain changes, an assessment of digestive health symptoms, bowel habits and quality of life.” He continued, “I am pleased to announce that this is one of a select few clinical studies in this space with “A” level clinical design, reporting and evidence”.
In the end, both probiotic strains achieved the primary objective by decreasing digestive related abdominal pain. In addition, secondary outcomes related to digestive health symptoms (gas, bloating, pain), quality of life, bowel normalization and stool consistency were also met.
UAS Laboratories LLC has delivered the highest quality, science-backed probiotics to the marketplace since 1979. Strictly dedicated to probiotic manufacturing, UAS is committed to designing innovative and effective formulations that strive to enhance wellness and quality of life.
Lakeview Equity Partners is a private equity investment fund that focuses on investments in Midwest-based, middle market companies. Lakeview Equity’s mission is to identify and invest in strong, well-managed companies to help them achieve continued growth and profitability and support ownership change, including ownership opportunities for managers and employees.